FDA Approves Ingrezza® Sprinkle (valbenazine) Capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.
Neurocrine Biosciences, Inc. has announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.
- Ingrezza Sprinkle provides an alternative administration option for those who experience dysphagia or
- have difficulty swallowing.
- Ingrezza (valbenazine) offers simple dosing that’s always one capsule, once daily with no complex titration. It is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers three effective dosages (40 mg, 60 mg and 80 mg) that can be adjusted by the healthcare provider based on patient response and tolerability.
Source: Neurocrine Biosciences, Inc.
